EBER1 and EBER2 are small non-coding RNAs expressed during latency. Both are believed to play an important role in oncogenesis, including cell transformation and inhibition of apoptosis. EBERs role in oncogenesis is believed to be derived from its interaction with human ribosomal protein L22 (RPL22) and subsequent destabilization of the p53 pathway.
Using proprietary screening technology, we have identified promising lead molecules that inhibit EBER1 from interacting with RPL22. Data suggests that these inhibitors are capable of restoring the p53 pathway and result in tumor suppression.
Copyright Ebvysis Pharmaceuticals Inc 2024
contact@ebvysis.com